Fig. 2From: Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment centerNet cost of PCSK9 inhibitor therapy, based on 61 patients’ cost history, assuming a 50 % reduction in CVD events on PCSK9 inhibitor therapyBack to article page